Allergan's Q3 Sales Get A Facelift From Botox; AbbVie Deal On Track

Botox maker Allergan plc AGN, which has agreed to be bought by AbbVie Inc ABBV for $63 billion, reported Tuesday ahead of the open with higher third-quarter revenue and an adjusted loss that was wider than expected.

The company said its pending acquisition by AbbVie is on schedule. 

Botox Boost For Top Line

Allergan said its third-quarter total net revenue climbed 3.6% year-over-year to $4.05 billion, ahead of the $3.88-billion consensus estimate.

Non-GAAP net revenues improved from $3.91 billion to $4.03 billion.

The company attributed the year-over-year growth to strong sales of the antipsychotic drug Vraylar, Botox Cosmetic, Juvederm, Botox Therapeutic, Ozurdex and Lo Loestrin. Vraylar sales grew 70% and U.S. Botox Cosmetic sales grew 10%.

Loss Wider Than Street Forecast

The net loss per share widened from 11 cents to $2.40. The non-GAAP net income per share remained flat at $4.25, higher than the Street forecast of $4.22.

Mixed Guidance

Allergan upwardly revised its 2019 guidance and said it expects total non-GAAP net revenue of $15.6 billion to $15.8 billion versus the previous guidance of $15.4 billion to $15.6 billion.

The company increased the low end of its loss per share estimate from a loss of $12.03 to a loss of $14.98 per share, but maintained the upper end of the range at a loss per share of $16.55.

Deal Itinerary Intact

In an update on its pending merger with AbbVie, Allergan said its shareholders voted Oct. 14 to approve the deal. The company also said it has received a second request from the FTC.

Both AbbVie and Allergan expect the deal to close in early 2020, according to Allergan. 

Allergan shares were down 0.25% at $178.36 at the time of publication Tuesday. 

Related Links:

The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight

Photo courtesy of Allergan. 

Posted In: BiotechEarningsNewsGuidanceTrading Ideas

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.